Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment

Matteo Morotti, F. Sozzi, Fausta Sozzi, Valentino Remorgida, Pier Luigi Venturini, Venturini PL, Simone Ferrero
European journal of obstetrics, gynecology, and reproductive biology · 2014 · vol. 183 , pp. 188–192 · doi:10.1016/j.ejogrb.2014.10.036 · PMID:25461377 · W1971584256
Non-randomised trial OA: closed CC0 ⤵ 85 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated dienogest's efficacy for persistent endometriosis-related pelvic pain in women already being treated with norethisterone acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate patient satisfaction at 6-months dienogest (DNG) treatment in women with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months of norethisterone acetate (NETA) therapy. STUDY DESIGN: This 24-weeks pilot open-label prospective study enrolled 25 women. The main outcome was the degree of patient satisfaction measured by using a Likert scale. Secondary outcomes were to evaluate differences in endometriosis-related pain, quality of life, sexual function changes and volumetric nodules changes during DNG compared to NETA treatment. RESULTS: Patient satisfaction improved at 3- and 6-months (p<0.001, respectively) treatment with DNG compared with baseline treatment with NETA. Six months DNG treatment decreased the intensity of all the endometriosis-associated pain (chronic pelvic pain, dyspareunia, dyschezia) compared to baseline (p<0.001 for all comparisons). Quality of life and quality of sexual life evaluated with the EHP-30 and FSFI, respectively, increased after 6 months treatment. The volume of the endometriotic nodules did not significantly change during treatment. CONCLUSIONS: This study confirms the efficacy of DNG in treating symptomatic women with rectovaginal endometriosis even in a particular endometriotic subpopulation of NETA "resistant" patients. Further randomized clinical trials comparing these two progestins both in first than second line are warranted.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Contraceptives, Oral Endometriosis Nandrolone Norethindrone Pelvic Pain Rectal Diseases Vaginal Diseases Adult Adult Contraceptives, Oral Contraceptives, Oral Endometriosis Endometriosis Endometriosis Female Female Follow-Up Studies Follow-Up Studies Humans Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-19T06:17:24.038039+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:14:41.184593+00:00
unpaywall
last seen: 2026-10-19T06:34:38.229974+00:00
License: CC0 · commercial use OK